Michael Severino was named Chief Executive Officer of Sarepta Therapeutics, Inc., succeeding Douglas Ingram, effective July 28, 2026. As of November 6, 2026, Sarepta Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 27, 2026, naming 2 appointments and 1 departure (Form 8-K, July 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Sarepta Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Michael Severino · Role: Chief Executive Officer · Effective: 2026-07-28 · 8-K, 2026-07-27
- · In / out: In · Person: Michael Severino · Role: Director · 8-K, 2026-07-27
- · In / out: Out · Person: Douglas Ingram · Role: Chief Executive Officer · 8-K, 2026-07-27
Sarepta Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-27. It names 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Sarepta Therapeutics, Inc. files it.
Also on the record for Sarepta Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13G/A, by AQR Capital Management, LLC | 5.05% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 8.4% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Vanguard Portfolio Management | 8.05% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 15.8% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.11% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 6.43% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G, by AQR Capital Management, LLC | 7.73% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 12.6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by D. E. Shaw & Co., L.P. | 1.9% of the class | 5%+ stakes | Source |
| November 10, 2025 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.4% of the class | 5%+ stakes | Source |
| September 8, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 10.89% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Sarepta Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Sarepta Therapeutics, Inc. and the records around it.
Sarepta Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- D. E. Shaw & Co., L.P. also filed stake reports on 28 other companies: Gossamer Bio, Inc. (Oct 2026), Sweetgreen, Inc. (Oct 2026), Venture Global, Inc. (Sep 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Watch Sarepta Therapeutics, Inc.
Get an email when Sarepta Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sarepta Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Sarepta Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sarepta Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-27 | In | Chief Executive Officer | 2026-07-28 | 8-K, 2026-07-27 | |
| 2026-07-27 | In | Director | 8-K, 2026-07-27 | ||
| 2026-07-27 | Out | Chief Executive Officer | 8-K, 2026-07-27 |
Who leads Sarepta Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Michael Severino, appointed, effective 2026-07-28 (filed 2026-07-27).
- Director: Michael Severino, appointed (filed 2026-07-27).
New leaders reset buying decisions — get the Full Report on Sarepta Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Sarepta Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Sarepta Therapeutics, Inc.Every change, in the filing's words
Appointed: Michael Severino, Chief Executive Officer, effective 2026-07-28
On July 23, 2026, the Board of Directors (the "Board") of Sarepta Therapeutics, Inc. (the "Company") appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026 (the "Effective Date").
Appointed: Michael Severino, Director
Also on July 23, 2026, the Board appointed Dr. Severino, effective as of the Effective Date, as a Class I director, to serve until the Company's 2028 annual meeting of stockholders.
Departing: Douglas Ingram, Chief Executive Officer
Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.
- Dr. Severino will succeed Douglas Ingram, the Company's current Chief Executive Officer.
- Mr. Ingram and the Company entered into a Consulting Agreement, dated July 26, 2026 (the "Consulting Agreement"), pursuant to which he will serve as consultant to the Company until December 31, 2026 in exchange for a monthly consulting fee of $15,000.
- Dr. Severino, age 60, most recently served as Chief Executive Officer and a member of the board of directors of Tessera Therapeutics, Inc., a clinical-stage biotechnology company, and as a CEO-Partner at Flagship Pioneering from June 2022 to July 2026.
- Prior to that, Dr. Severino served as the Vice Chairman and President of AbbVie Inc., a pharmaceutical company, from December 2018 until June 2022, where he was responsible for research and development and oversaw corporate strategy.
- At AbbVie, he also served as Executive Vice President of Research and Development, Chief Scientific Officer.
- Prior to joining AbbVie, Dr. Severino served in roles of increasing responsibility at Amgen, Inc., leading to his appointment as Senior Vice President, Global Development and Chief Medical Officer.
- Dr. Severino received his M.D. from the Johns Hopkins University and his Bachelor of Science degree from the University of Maryland.
Tools for this story
Each opens in a new tab, filled in for Sarepta Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.